Navigation Links
Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast Cancer
Date:9/23/2009

BERLIN, September 23 /PRNewswire/ --

- The Austrian Breast and Colorectal Cancer Study Group Present Data Which Highlight Benefits of Adding capecitabine to epirubicin and docetaxel in the Neoadjuvant Setting

Data from the ABCSG-24 study presented today at the joint 15th ECCO and 34th ESMO congress in Berlin, Germany, show that adding capecitabine (Xeloda(R)) to anthracycline- and taxane-containing regimens prior to surgery (neoadjuvant therapy) completely eradicated the tumour in 24% of women with HER2-positive or HER2-negative early breast cancer. This is an impressive finding since the proportion of women achieving total tumour eradication with standard chemotherapy[*] for HER2-positive or HER2-negative early breast cancer is less than 20% (range 6-18%).[1]

"These new data show that adding capecitabine to epirubicin and docetaxel neoadjuvant regimens when treating women with early breast cancer, results in increased efficacy compared to epirubicin and docetaxel alone. This new data could lead to improvements in treatment for women with early stages of the disease as the increased efficacy may result in prolonged overall survival," said Professor Günther Steger, Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, General Hospital Vienna, Vienna, Austria.

Despite recent advances, there is still an unmet need in the treatment and management of early breast cancer with relapse occurring in approximately 30-50% of patients, depending on individual risk factors, even after chemotherapy.[2] In addition to the ABCSG-24 study, several other studies of neoadjuvant combination regimens that included capecitabine have shown positive efficacy results.[3],[4],[5],[6],[7],[8],[9] The therapeutic success in these studies was measured as complete pathological response (complete disappearance of tumour cells in the breast and in the lymph nodes), which is
'/>"/>

SOURCE Austrian Breast & Colorectal Cancer Study Group (ABCSG)
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
2. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
3. Zetia Does Not Reduce Carotid Plaque Size When Added to Zocor
4. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
5. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
6. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
7. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
8. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
11. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... IRVINE, Calif., Aug. 4, 2015  Syneron Medical Ltd. (NASDAQ: ... announced financial results for the three month period ended June ... Recent Non-GAAP 1 Highlights: , ... constant currency. , North American product sales grew 45% ... in constant currency, including 14% product growth in the EMEA ...
(Date:8/3/2015)...   The Intellectual Property and Science business ... of intelligent information for businesses and professionals announced ... R&D Factbook , the biopharmaceutical industry,s leading resource ... in R&D, the analysis identifies a surge in ... forecasts sales to reach $1.3 trillion by 2018. ...
(Date:8/3/2015)... GLENWOOD, Ill. , Aug. 3, 2015  Landauer, ... personal and environmental radiation measurement and monitoring, outsourced medical ... announced it will release financial results for the fiscal ... August 10, 2015. The Company will ... August 11, 2015 at 9:00 a.m. Central Time (10:00 ...
Breaking Medicine Technology:Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17Pharma Sales to Grow Beyond $1 Trillion 2Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2
... Feb. 1, 2011 Anthera Pharmaceuticals, Inc. (Nasdaq: ... treat serious diseases associated with abnormal auto-immune responses and ... Thompson to its Board of Directors. Currently, Dr. Thompson ... founder and Managing Director of Strategicon Partners, an investment ...
...  China Medicine Corporation (OTC Bulletin Board: ... and distributor of Western pharmaceuticals, traditional Chinese medicines ... Republic of China, today announced that the Company ... Ministry of Agriculture ("MOA") for the Company,s proprietary ...
Cached Medicine Technology:Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors 2China Medicine Corporation Receives Manufacturing License for rADTZ 2China Medicine Corporation Receives Manufacturing License for rADTZ 3
(Date:8/4/2015)... ... August 04, 2015 , ... Wimbledon Health Partners , ... NCV testing, announced their collegiate division, Wimbledon U , continues to not ... program at a time. , “Wimbledon U welcomes the eight new ...
(Date:8/4/2015)... ... ... An article published July 27th by the Providence Journal detailed ... people to lose weight. Specifically the study compared control patients with those who were ... financial incentive to the overall incentive of increased health. According to Michael Feiz, M.D., ...
(Date:8/4/2015)... , ... August 04, 2015 , ... Bayco Products, Inc. ... enough to fit, for example, on hard hats that have a flip-up face shield. ... allows users to work without having to remove their headlamp when raising or ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, CA ... only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands in ...
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide Power Products acquires new ... its reach in Texas. Effective July 1st of this year, Worldwide Power Products ... With the North Texas acquisition, Worldwide Power Products (“WPP”) now services 1000 ...
Breaking Medicine News(10 mins):Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:North Texas Acquisition Press Release 2
... named REACH: Registration, Evaluation and Authorization of Chemicals, has shifted ... manufacturers. ,The chemical companies would be bound by ... of their business. ,This law aims to make ... safe for users and the environs. ,The European ...
... Surgical Adjuvant Breast and Bowel Project (NSABP) B-33 ... Cancer Symposium, showed that// postmenopausal women with hormone ... years of tamoxifen were 56% less likely to ... who received placebo (P=0.004). ,“Aromasin provided ...
... in occupational settings and in the environment has been ... Journal of Occupational and Environmental Medicine, official publication of ... is a special issue providing updates on particles and ... types of studies for some particles in terms of ...
... soy-based substance. A US based study finds: BBIC improves ... multiple// sclerosis. ,A group of animals with ... animals also suffering from the same disease received a ... to walk, while those that didn't get the drug ...
... the Bombay Hospital and three other firms are planning to ... ,The Jaipur Development Authority would allot land for the five ... a Rs.2 billion Medi-City to be built here in three ... ,The state plans to be strict with the investors ...
... In the absence of vaccine against HIV/AIDS, the 'social vaccine' ... of the deadly virus, a top UN official here said ... to fight against the HIV/AIDS," said Peter Piot, executive director ... vaccine I mean to create a mass awareness to educate ...
Cached Medicine News:Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 2Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 3Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 4Health News:Inhaled Particles Increases the Risk of Lung Cancer 2
... detects the presence of Hemoglobin S ... of reconstituted solubility buffer and 20l of ... cell hemoglobin control. Each test kit contains ... two buffer dispensing caps and two vials ...
... Streck Cytometry Concentrate is for use ... by flow cytometry. Each 70ml bottle of ... fluid with distilled water. Compared to Cubitainers, ... usable space and saves money without compromising ...
... is an assayed control for monitoring immunophenotyping ... accuracy and reproducibility of all the steps ... red blood cell lysis. Reference values for ... B lymphocytes, granulocytes, monocytes, and NK cells. ...
Use Streck-Sheath to count and classify white blood cells on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf life is two years from date of manufacture...
Medicine Products: